Evidence map›Paper›PMID 36809562›Full record

ArticleAmino acids2023

A new

Hongliang Wang, Kaixin Qin, Dongmei Shi, Ping Wu, Xinzhong Hao, Haiyan Liu, Jie Gao, Jianguo Li, Zhifang Wu, Sijin Li

Abstract read
PubMed Publisher
In one paragraph

Article in Amino acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. International journal of molecular sciences · 2025
    Article
  3. Serum Metabolites as Diagnostic Biomarkers in Patients with Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hongliang Wang *Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China. hongliang0812@163.com.
Kaixin Qin *Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Dongmei ShiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Ping WuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Xinzhong HaoDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Haiyan LiuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Jie GaoNational Atomic Energy Agency Nuclear Technology (Nonclinical Evaluation of Radiopharmaceuticals) Research and Development Center, China Institute for Radiation Protection, Taiyuan, 030006, Shanxi, People's Republic of China.
Jianguo LiNational Atomic Energy Agency Nuclear Technology (Nonclinical Evaluation of Radiopharmaceuticals) Research and Development Center, China Institute for Radiation Protection, Taiyuan, 030006, Shanxi, People's Republic of China.
Zhifang WuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China.
Sijin LiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, 030001, Shanxi, People's Republic of China. lisjnm123@163.com.
First Hospital of Shanxi Medical University · CNShanxi Medical University · CN

Funding

Central leading local science and Technology Development Fund Project YDZJSX2022A058Four "Batches" Innovation Project of invigorating Medical through Science and Technology of Shanxi Province 2022XM38National Natural Science Foundation 81471695National Natural Science Foundation 81971655National Natural Science Foundation 82001873National Natural Science Foundation 82027804the Open Fund Projects of China Institute for Radiation Protection Scientific Research Platform No. CIRP-CAEA20210201
6 · The paper itself

Abstract

Ornithine metabolism plays a vital role in tumorigenesis. For cancer cells, ornithine is mainly used as a substrate for ornithine decarboxylase (ODC) for the synthesis of polyamines. The ODC as a key enzyme of polyamine metabolism has become an important target for cancer diagnosis and treatment. To non-invasively detect the levels of ODC expression in malignant tumors, we have synthesized a novel

Indexed as

Gallium RadioisotopesNeoplasmsAnimalsOrnithinePositron-Emission TomographyRatsTissue DistributionGallium RadioisotopesOrnithineMolecular probesOrnithinePETPolyamines

Identifiers

PMID36809562
OpenAlexW4321436935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.